Results 361 to 370 of about 1,468,461 (396)
Some of the next articles are maybe not open access.
Producing Bispecific and Bifunctional Antibodies
2004Bispecific antibodies are artificially engineered monoclonal antibodies (MAbs) that consist of two distinct binding sites and are capable of binding two different antigens noncovalently. They can be produced by chemical cross-linkage, genetic engineering, or somatic hybridization.
Mavanur R. Suresh, Dipankar Das
openaire +3 more sources
Bispecific Antibody Therapy in Hemophilia
New England Journal of Medicine, 2017Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire +3 more sources
Introduction: bispecific antibodies
Journal of Immunological Methods, 2001George J. Weiner +2 more
openaire +3 more sources
Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies
2019Bispecific antibodies are an emerging novel therapeutic construct used to treat a variety of cancers. These drugs utilize a small fusion protein to link two single-chain antibodies, allowing for simultaneous binding of two different epitopes. Bispecific T-cell engagers (BiTE) are a subset of bispecific antibodies that bind the target antigen on the ...
Stacy Cooper, Patrick A. Brown
openaire +2 more sources
Bispecific antibody therapy for lymphoma
Best Practice & Research Clinical HaematologyThe rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard +1 more
openaire +2 more sources
Bispecific antibodies in myeloma
Hématologie, 2021Sophie Le Grand, Aurore Perrot
openaire +1 more source
The present and future of bispecific antibodies for cancer therapy.
Nature reviews. Drug discoveryChristian Klein +3 more
semanticscholar +1 more source
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Nature, 2022Yunlong Cao, Jing Wang, Fanchong Jian
exaly
Bispecific and multispecific antibodies in oncology: opportunities and challenges.
Nature Reviews Clinical OncologyM. Goebeler, Gernot Stuhler, Ralf Bargou
semanticscholar +1 more source